Fauna Bio
Fauna Bio is an AI-driven drug discovery company leveraging evolutionary biology and genetic data from extreme mammals to identify novel drug targets for human diseases. Using its proprietary Convergence™ AI platform and a unique biobank of genetic data from diverse species, Fauna Bio replicates natural disease resistance mechanisms to develop new therapeutics. The company focuses on a broad range of diseases including obesity, neurodegeneration, heart failure, kidney disease, and inflammatory conditions, with a pipeline advancing from discovery to clinical stages. Fauna Bio has a strategic collaboration with Eli Lilly valued up to $494 million for obesity drug target discovery, positioning it strongly in a market opportunity exceeding $60 billion. The company integrates comparative genomics, AI, and functional genomics to accelerate drug discovery efficiently and cost-effectively.
Fauna Bio
Fauna Bio is an AI-driven drug discovery company leveraging evolutionary biology and genetic data from extreme mammals to identify novel drug targets for human diseases. Using its proprietary Convergence™ AI platform and a unique biobank of genetic data from diverse species, Fauna Bio replicates natural disease resistance mechanisms to develop new therapeutics. The company focuses on a broad range of diseases including obesity, neurodegeneration, heart failure, kidney disease, and inflammatory conditions, with a pipeline advancing from discovery to clinical stages. Fauna Bio has a strategic collaboration with Eli Lilly valued up to $494 million for obesity drug target discovery, positioning it strongly in a market opportunity exceeding $60 billion. The company integrates comparative genomics, AI, and functional genomics to accelerate drug discovery efficiently and cost-effectively.